Standard BioTools

Standard BioTools Operating Expenses

The Total Operating Expenses of Standard BioTools (LAB) as of Oct 8, 2026 is 135.85 M USD. In the previous year, Total Operating Expenses was 219.02 M USD — a change of -37.97% (lower).

Operating Expenses

135.85 MUSD

YoY

-37.97%

Last updated:

Total Operating Expenses of Standard BioTools is 2025 135.85 M USD. Total Operating Expenses of Standard BioTools was 2024 219.02 M USD. It decreases by -37.97% lower compared to the previous year.

The Standard BioTools Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2018
109.81 M USD
Jan 1, 2019
116.12 M USD
Jan 1, 2020
134.36 M USD
Jan 1, 2021
136.83 M USD
Jan 1, 2022
152.14 M USD
Jan 1, 2023
124.83 M USD
Jan 1, 2024
219.02 M USD
Jan 1, 2025
135.85 M USD
The Standard BioTools Operating Expenses history
YEAROperating ExpensesYoY
135.85 MUSD-37.97%
219.02 MUSD+75.45%
124.83 MUSD-17.95%
152.14 MUSD+11.19%
136.83 MUSD+1.84%
134.36 MUSD+15.71%
116.12 MUSD+5.74%
109.81 MUSD-0.48%
110.34 MUSD-16.17%
131.63 MUSD+235.24%
39.26 MUSD-9.58%
43.42 MUSD—
Access this data via the Eulerpool API

Standard BioTools Stock analysis

What does Standard BioTools do? Fluidigm Corp is a biotechnology company specializing in innovative devices and solutions for DNA sequencing. The company was founded in 1999 in San Francisco and is currently headquartered in South San Francisco. It developed the Microfluidic Technology-Sensor, which allows for handling tiny amounts of fluids in a small space. This technology has enabled researchers to analyze complex samples and collect data with high accuracy. The company operates in two main segments: Analytical Instruments and Sample Preparation. In the Analytical Instruments segment, Fluidigm offers various devices suitable for DNA sequencing, including the Juno, C1, and Biomark platforms. It also provides a wide range of consumables to facilitate sample preparation. The Sample Preparation segment offers products and services to prepare and process samples for analysis, including microfluidic technology chips and modules, single-cell sequencing systems, and products for next-generation sequencing. Fluidigm serves customers in various industries, such as genomics research, cancer research, and medical fields, with a strong presence in North America, Europe, and Asia. The company is known for its continuous investment in research and development, as well as its innovative technologies and patents. Overall, Fluidigm's Microfluidic technology platform allows researchers to collect data in a small space with high accuracy. With a diversified portfolio of products and services, the company is well-positioned to continue growing and expanding its market presence in the coming years. Standard BioTools is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Standard BioTools stock

Total Operating Expenses of Standard BioTools is 135.85 M USD in 2025.

Total Operating Expenses of Standard BioTools changed from 219.02 M USD to 135.85 M USD, representing a -37.97% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses Standard BioTools since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's Standard BioTools historically and in real time.

Access this data via the Eulerpool API

Income Statement — Standard BioTools

All Key Metrics — Standard BioTools